AbbVie Inc. reported a significant Q1 revenue of $15 billion, reflecting a 12.4% year-over-year increase, and exceeding analyst predictions. The company also posted adjusted earnings of $2.65 per share, beating estimates and prompting Bank of America to upgrade its stock rating to 'Buy' with a new price target of $234. Following this strong performance, AbbVie raised its full-year earnings guidance, underscoring its commitment to growth through substantial investments in manufacturing and an innovative product pipeline.
“AbbVie Inc. · shares gained · percentage · 3.1%”
“AbbVie (ABBV) · revenue climbing · 12.4% year-over-year to $15 billion · 15 billion”
“AbbVie · demonstrates · commitment to a thriving biotech ecosystem in Quebec · true”
“the AbbVie Biotech Innovators Award · underscores · AbbVie’s commitment · to fostering a thriving life sciences ecosystem”
“AbbVie Inc. (NYSE:ABBV) · is included among · the 10 Best Large Cap Dividend Growth Stocks to Invest in”
“Bank of America · upgraded · AbbVie Inc. (NYSE:ABBV) · to Buy from Neutral”
“Bank of America · lifted · the price target on AbbVie · to $234 from $226”
“AbbVie · is offering · one of the best ex-pipeline growth profiles in large cap pharma · with room for upside”
“AbbVie management · tied the quarter’s performance · to specific portfolio drivers”
“AbbVie management · noted the closing of · the RemeGen Co., Ltd. agreement”
“AbbVie · plans to invest · $1.4 billion · to build a pharmaceutical manufacturing campus in North Carolina”
“AbbVie · plans to invest · $380 million · to construct two new plants in North Chicago”
